drugset / Trial / NCT03624920
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
RandomizedCrossoverTriple-blindTreatment
Summary
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose levels of THN102 to placebo in patients suffering from Parkinson's disease associated with excessive daytime sleepiness.
Timeline
- Start
- 2018-07-12
- Primary completion
- 2019-12-20
- Completion
- 2020-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Modafinil | Small molecule | 200 mg | — |
| Subject | flecainide | Small molecule | 2 mg | — |
| Subject | flecainide | Small molecule | 18 mg | — |